Archive — US — techcrunch
Australian health tech startup Harrison.ai scores $112M Series C
Harrison.ai, an Australian health tech startup, raised $112M in Series C funding to enhance its AI-powered medical diagnostic tools for radiology and pathology. Founded by brothers Aengus and Dimitry Tran, the Sydney-based company aims to improve diagnostic accuracy and efficiency in healthcare, now operating in 15 countries with plans to expand in North America.
Key points
- Harrison.ai raised $112 million in Series C funding, bringing total investment to $240 million.
- Funds will be used to scale operations in key markets including the U.S., EMEA, and Asia Pacific.
- The company offers two main products: Annalise.ai for radiology and Franklin.ai for pathology.
- AI tools assist in early disease detection, improving patient outcomes and reducing wait times.
- Started by brothers Aengus and Dimitry Tran in 2018, the company addresses the global shortage of skilled clinicians.
- Harrison.ai's technology has gained regulatory clearance in 40 countries, including 12 FDA approvals.
Why it matters
- In 2025, AI in healthcare is expected to increasingly replace manual processes, driven by such innovations.
- Harrison.ai addresses the growing global demand for diagnosis, particularly in light of the COVID-19 pandemic.
- The rise of telemedicine and digital health platforms aligns with Harrison.ai's mission to enhance healthcare delivery.
- AI-enabled diagnostics are becoming critical in tackling both chronic and acute health challenges globally.
With substantial funding and a clear expansion strategy, Harrison.ai positions itself at the forefront of AI-enhanced diagnostics, promising more accurate and efficient healthcare solutions that may revolutionize patient care globally.